Over the last 6 months, we have all been severely impacted by the COVID-19 pandemic around the world. An unprecedented global effort has taken place to contain and hopefully reduce the impact of COVID-19 on everyone’s lives. Healthcare professionals have been at the frontline of this initiative with the support of public and private sectors. Academic, biopharmaceutical and diagnostic research has increased our knowledge of the SARS-CoV-2 virus and the physiopathology of the COVID-19 infection. In response, Public Health and Regulatory Authorities, policy makers and governments are rapidly adapting to mitigate the risk of COVID-19 spread in the population. In this context, In Vitro Diagnostic (IVD) device manufacturers have quickly produced serology tests detecting the presence of antibodies to SARS-COV-2 virus. Utilizing such tests as the ultimate sentinel to make decisions to cope with and react to the COVID-19 pandemic is being considered. But can it be that simple?Agenda:
The COVID-19 pandemic has impacted laboratory testing in global clinical trials of both COVID-19 and non-COVID-19 treatments. This webinar examines laboratory testing and operational considerations required in the time of COVID-19, and specifically for clinical trials studying COVID-19 treatments. To what degree will process changes remain after the pandemic subsides?
Gain insight into COVID-19 test development, and how genomics, flow cytometry, immunoassay, and bioanalysis can support COVID-19 studies. Our subject matter experts will discuss business continuity measures, such as temperature monitoring and lab space redesigns, and adaptations in robust specimen collection kit ordering and tracking, as well as sample tracking, which have increased in complexity from inter-country flight restrictions. Learn about the implications of recent surges in demand for home specimen collection and local lab data management.Agenda: